ArticleFrontiers in immunology2025
Novel pan-cancer T cell exhaustion signature forecasts immunotherapy response and unveils BCAP31 in macrophages as a therapeutic target in neuroblastoma.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Gaining insights into the molecular features associated with T cell exhaustion (TEX) can offer fresh perspectives on predicting treatment responses, and we aim to investigate TEX-related tumor associated macrophages (TAM) subset to deeply understand underlying mechanisms of immune exhaustion. Methods: We performed pan-cancer single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics RNA sequencing (stRNA-seq) analyses to investigate the subtype of TEX-associated TAMs, exploring its spatial distribution characteristics in context of immunotherapy. The pan-cancer scRNA-seq and RNA-seq datasets were incorporated to develop the STMN2+ Macrophage Signature (STMN2.SIG), which predicts immunotherapy response based on integrative machine learning techniques. Comprehensive scRNA-seq analysis, with Results: A macrophage subset, STMN2+ TAMs, and an epithelial subtype, S phase Sympathoblasts were identified as TEX-related cellular subpopulations. A higher proportion of STMN2+ TAMs was observed in non-responders compared to responders in pan-cancer immunotherapy landscape. Pan-cancer STMN2.SIG performed well in predicting immunotherapy response in pan-cancer cohorts, potentially linked to intercellular interactions between STMN2+ TAMs and CD8+ Tex cells. stRNA-seq analysis confirmed that interactions and cellular distances between STMN2+ TAMs and CD8+ Tex cells impact therapy efficacy. In a co-culture system, silencing BCAP31 on TAMs drives CD8+ T cells toward an effector state in NB. And BCAP31 on TAMs is associated with modulation of JAK2-STAT3 pathway in tumor cells. Conclusion: Our study provides pan-cancer STMN2.SIG as an outperforming approach for patient selection of immunotherapy, and advances our understanding of TAM biology and suggests potential therapeutic strategies for downregulation of BCAP31 in TAMs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.